Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

Objective: To evaluate the efficacy and safety of pegylated interferon alpha-2b (PEG IFN-α2b) administered in conjunction with the standard of care (SOC) in subjects with moderate coronavirus disease-19 (COVID-19). Methods: In this study, adult subjects with confirmed moderate COVID-19 were randomiz...

Full description

Bibliographic Details
Main Authors: Shashi Bhushan B L, Sunil Wanve, Parshottam Koradia, Vinay Bhomia, Pravin Soni, Sisir Chakraborty, Akash Khobragade, Shashank Joshi, Sanjeev Kumar Mendiratta, Kevin Kumar Kansagra, Anurag Parihar, Sunil Sharma, Jatin Patel
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:International Journal of Infectious Diseases
Subjects:
Pegylated interferon alpha-2b (PEG IFN-α2b)
SARS-CoV-2
Phase 3
Moderate subjects
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221006779

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221006779

Similar Items